Express Pharma
Home  »  Pharma Ally  »  Dr Markus Wyss, CEO, Camag, Switzerland gives insight on HPTLC products

Dr Markus Wyss, CEO, Camag, Switzerland gives insight on HPTLC products

53

Visits Ahmedabad and Chandigarh explaining the potential of HPTLC analysis, in every kind of organic analysis

Dr Markus Wyss, CEO, Camag, Switzerland recently visited India to speak about latest developments in High Performance Thin Layer Chromatography (HPTLC) products and methodology. He addressed analysts in Ahmedabad and Chandigarh explaining the potential of HPTLC analysis, in every kind of organic analysis, using cannabis as an example.

He commented that India has a lot of HPTLC equipment and the need of the hour is to perform HPTLC as per the USP’s SOP, which requires a change in methodology and not additional equipment. Three instruments were on demo-cum display.

The patented ‘TLC-MS interface’ is an accessory to LC-MS or GC-MS to record MS of HPTLC bands of interest. The patented ‘Derivatiser’ that requires only 2ml of reagent for spraying on chromatographed HPTLC plates. Last but the most important from regulatory point of view, automated development chamber which offers a closed system with extremely controlled parameters for very reproducible results. All the three instruments represent giant steps in HPTLC.

Dr Wyss appreciated the use of instrumental TLC so widely used in India for research and quality control and happy that most will shift to HPTLC.

Comments are closed.